A Study to Assess the Safety and Effectiveness of Durogesic (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Long-term Narcotic Pain Relief Therapy

Inclusion Criteria: * Patients with a confirmed malignancy (whose pain is judged by the investigator to be caused by the malignancy), or patients with other life-threatening/terminal disease whose pain requires treatment with strong opioid analgesia * requiring treatment of pain with a strong opioid and who are expected to continue to require treatment with a strong opioid for the duration of the study * receiving a stable dose of immediate-release oral morphine or sustained-release morphine (minimum daily dose of morphine is 30 mg/day) for at least 48 hours immediately prior to entry into the study Exclusion Criteria: * Patients with a history of allergy or hypersensitivity to fentanyl or morphine * have active skin disease that precludes application of Durogesic® or which may affect the absorption of fentanyl * have a clinical condition that in the investigator's judgment prevents participation in the study * have participated in any other drug trial relating to pain control within one month of study entry * currently participating in any other study or research project which would interfere with this trial.